Adam Brufsky, MD, PhD, FACP, discusses the tnAcity trial, which is aimed to clarify how best to use existing drugs in patients with triple-negative breast cancer.
Adam M. Brufsky, MD, PhD
Advertisement
Adam M. Brufsky, MD, PhD, of the University of Pittsburgh Medical Center Hillman Cancer Center
Articles by Adam M. Brufsky, MD, PhD
Dr. Adam Brufsky from the University of Pittsburgh School of Medicine Advises Doctors on Bevacizumab (Avastin) for Breast Cancer
Dr. Adam Brufsky from University of Pittsburgh School of Medicine, Discusses Bevacizumab Benefits in TNBC
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
4
NMA Associates MRD-Negative CR With PFS in Earlier-Line R/R Myeloma
5